AlzeCure Pharma AB

ALZCUR

SE0010133785

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 09:30:00 28/06/2024 pm IST			5-day change	1st Jan Change
1.905 ^SEK	-0.26%		+1.60%	-38.75%

13/06	Alzecure Pharma AB Announces Positive Clinical Results with Painless ACD440 Against Neuropathic Pain	CI
14/05	AlzeCure Pharma AB Approves the Election of Jan Lundberg as New Ordinary Members of the Board of Directors	CI

AlzeCure Pharma AB Appoints Eva Lilienberg as Ordinary Members of the Board of Directors

May 17, 2021 at 05:30 pm IST

AlzeCure Pharma AB (publ) announced that at its AGM held on May 17, 2021, the shareholders approved the appointment of Eva Lilienberg as ordinary members of the board of directors.

Latest news about AlzeCure Pharma AB

Alzecure Pharma AB Announces Positive Clinical Results with Painless ACD440 Against Neuropathic Pain	13/06	CI
AlzeCure Pharma AB Approves the Election of Jan Lundberg as New Ordinary Members of the Board of Directors	14/05	CI
AlzeCure Pharma AB Reports Anti-Inflammatory Effects with NeuroRestore ACD856 with Relevance to Alzheimer's Leading to New Patent Application	13/05	CI
AlzeCure Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	25/04	CI
Jan Lundberg acquired an unknown minority stake in AlzeCure Pharma AB (OM : ALZCUR).	10/04	CI
AlzeCure Pharma AB Presents New Data Regarding the TrkA-NAM Pain Project at IASP 2024	03/04	CI
AlzeCure Presents New Preclinical Data with NeuroRestore ACD856 at Leading Alzheimer's Conference	07/03	CI
AlzeCure Pharma AB Publishes Clinical Results Supporting Continued Development of NeuroRestore ACD856 Against Alzheimer's	05/03	CI
AlzeCure Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	27/02	CI
AlzeCure Pharma AB Announces Live Expert Event on Alzheimer's Around Highly Current Gamma-Secretase Modulators	12/02	CI
AlzeCure Pharma AB Gets Late Breaking Abstract of New Preclinical Data with ACD856 Accepted at AD/PD 2024 Conference	06/02	CI
AlzeCure Pharma AB Selects Drug Candidate and Enters Next Phase of Development with Trka-Nam Acd137 Against Severe Pain	29/01	CI
AlzeCure Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11	CI
AlzeCure Pharma AB Presents Disease-Modifying Data with NeuroRestore ACD856 At Alzheimer's Conference CTAD	25/23/25	CI
Sweden's AlzeCure Pharma Gets Japanese Patent Approval for Alzheimer's Drug Candidate	19/23/19	MT
AlzeCure Pharma AB Announces Japenese Patent Office Grants Patent Covering its Leading Candidate Drug ACD856	19/23/19	CI
Alzecure Presents Clinical Phase Ii-Data with Acd440 for Neuropathic Pain At Pain Conference	12/23/12	CI
AlzeCure Gets Presentation Accepted on Disease-Modifying Effects of Acd856 At Alzheimer's Conference	26/23/26	CI
AlzeCure Pharma AB Presents Positive Phase II Clinical Data with ACD440 Against Neuropathic Pain at EFIC 2023 Conference	20/23/20	CI
AlzeCure Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	24/23/24	CI
AlzeCure Pharma Publishes the Positive Clinical Results from the Phase I Trial of NeuroRestore ACD856 Against Alzheimer's	09/23/09	CI
AlzeCure Pharma AB Publishes New Disease Modifying Data with Neurorestore ACD856 Against Alzheimer's and Cognitive Disorders	11/23/11	CI
AlzeCure Pharma AB Announces New Article on Antidepressive Effects with NeuroRestore ACD856	03/23/03	CI
Alzecure Announces Positive Phase IIa Clinical Study Data in Neuropathic Pain with the Non-Opioid ACD440	24/23/24	CI
AlzeCure Pharma AB Appoints Janet Hoogstraate to its Board	19/23/19	CI

AlzeCure Pharma AB is a Sweden-based pharmaceutical research and development company with a primary focus on Alzheimerâs disease and other brain disease indications. The Company develops five drug candidates within its two main research programs, NeuroRestore and Alzstatin. The drug candidates in NeuroRestore stimulate a central signaling pathway in the brain that is essential for the functioning of nerve cells and has a strong genetic link to cognitive disorders, such as Alzheimer's disease. The main drug candidate, ACD855, is an already approved veterinary medicine available for the treatment of central nervous system (CNS) indications in animals and has undergone preclinical trials for human indications of impaired cognitive disorders. Alzstatin focuses on reducing the production of toxic amyloid beta (AÎ²) protein in the brain. AÎ² plays a central role in the pathology of Alzheimerâs disease and starts to accumulate in the brain many years before the first symptoms are recognized.

Sector

Biotechnology & Medical Research

Calendar

26/08/2024 - Q2 2024 Earnings Release

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ALZECURE PHARMA AB	-38.75%	1.12Cr
VERTEX PHARMACEUTICALS INCORPORATED	+15.20%	12TCr
REGENERON PHARMACEUTICALS, INC.	+19.67%	11TCr
ARGENX SE	+18.95%	2.6TCr
BIONTECH SE	-23.86%	1.94TCr
GENMAB A/S	-19.03%	1.59TCr
BEIGENE, LTD.	-20.90%	1.51TCr
WUXI APPTEC CO., LTD.	-46.14%	1.51TCr
SAREPTA THERAPEUTICS, INC.	+63.85%	1.49TCr
NEUROCRINE BIOSCIENCES, INC.	+4.49%	1.39TCr

Bio Therapeutic Drugs